AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC 50 s of 2 nM ( TrkA ), 8 nM ( TrkB ), 24 nM (FGFR1), 52 nM ( Flt3 ), 55 nM ( Ret ), 84 nM (MuSk), 99 nM ( Lck ), respectively.
Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Pain | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Trk Receptor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.